Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension

Kidney International

Volumn 53, Issue 6, 1998, Pages 1748-1754

  Vaziri, Nosratola D ^a,b   Oveisi, Fariba ^a   Ding, Yaoxian ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antioxidants; Arteriosclerosis; Chronic renal failure; Hypertension; Lazaroid; Nitric oxide; Oxygen free radicals

Indexed keywords

21 [4 [2,6 BIS(1 PYRROLIDINYL) 4 PYRIMIDINYL] 1 PIPERAZINYL]PREGNA 1,4,9(11) TRIENE 3,20 DIONE; CATALASE; DIMETHYLUREA; MALONALDEHYDE; NITRATE; NITRITE; OXYGEN RADICAL; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEPHRECTOMY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RENOVASCULAR HYPERTENSION; URINARY EXCRETION;

EID: 0031749824     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1998.00947.x     Document Type: Conference Paper

References (38)

1. KISHORE BK, GEJYO F, ARAKOWA M: Malondialdehyde - A putative uremic toxin. IRCS Med Sci 11:750-751, 1983
2. TIZNADEL K, PAWLICKI L, KEDZIORE J, LUCIOK M, BLASZEZYK J, BUCZYNSKI A: Superoxide anion generation, erythrocyte superoxide dismutase activity and lipid peroxidation during hemoperfusion and hemodialysis in chronic uremic patients. Free Ridic Biol Med 6:393-397, 1989
3. PAUL JL, MAN NK, MOATTI N, RAICHVARG D: Membrane phospholipid peroxidation in renal insufficiency and chronic hemodialysis. Nephrologie 12:4-7, 1991
4. DURAK I, AKYOL O, BASESME E, CANBOLATO, KAVUTCU M: Reduced erythrocyte defense mechanisms against free radical toxicity in patients with chronic renal failure. Nephron 66:76-80, 1994
5. KESTENBAUM RS, CARUSO C, BERLYNE GM: Reduced superoxide dismutase activity in erythrocytes of dialysis patients: A possible factor in the etiology of uremic anemia. Nephron 55:251-253, 1990
6. ESCBACH JW, ADAMSON JW: Anemia of end-stage renal disease (ESRD). Kidney Int 28:1-5, 1985
7. TURI S, NEMETH I, VARGHA I, MATKOVICKS B, DUBOS E: Erythrocyte defense mechanisms against free oxygen radicals in haemodialysed uraemic children. Pediatr Nephrol 5:179-183, 1991
8. SMITH MC, DUNN MJ: Hypertension in renal parenchymal disease, in Hypertension: Pathophysiology, Diagnosis, and Management (2nd ed), edited by LARAGH JH, BRENNER BM, New York, Raven Press, 1995, pp 2081-2102
9. KIM KE, ONESTI G, DEL GUERCIO ET, GRECO J, FERNANDES M, EIDELSON B, SWARTZ C: Sequential hemodynamic changes in end-stage renal disease and the anephric state during volume expansion. Hypertension 2:102-110, 1980
10. LIVITAN D, MASSRY SG, ROMOFF M, CAMPESE V: Plasma catecholamines and autonomic nervous system function in patients with early renal insufficiency and hypertension: Effect of clonidine. Nephron 36:24-29, 1984
11. DZAU VJ: Significance of the vascular renin-angiotensin pathway. Hypertension 8:553-559, 1986
12. WEIDMANN P, SCHOHN D, GNADINGER MP, BURGISSER E, FERRIER C, JAHN H: Hypertensive dysregulation and its modification by calcium channel blockade in nonoliguric renal failure. Am J Nephrol 9:269-278, 1989
13. CONVERSE RL, JACOBSEN TN, TOTO RD, JOST CMT, CONSENTINO F, FOUAD-TARAZI F, VICTOR RG: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327:1912-1918, 1992
14. OHTA K, HIRATA Y, SHICHIRI M, KANNO K, EMORI T, TOMITA K, MARUMO I: Urinary excretion of endothelin-1 in normal subjects and patients with renal disease. Kidney Int 39:307-311, 1991
15. KOYAMA H, TABATA T, NISHZAWA Y, INOUE T, MORII H, YAMAJI T: Plasma endothelin levels in patients with uremia. Lancet 1:991-992, 1989
16. SCHIFFRIN EL, THIBAULT G: Plasma endothelin in human essential hypertension. Am J Hypertens 4:303-308, 1990
17. RESNICK L: Cellular ions in hypertension, insulin resistance, obesity, and diabetes: A unifying theme. J Am Soc Nephrol 3(Suppl 4):S78-S85, 1992
18. KAUPKE CJ, ZHOU XJ, VAZIRI ND: Cytosolic ionized magnesium concentration in ESRD: Effect of hemodialysis. ASAIO J 39:M614-M617, 1993
19. KRAMER HJ, MEYER-LEHNERT H, MICHEL H, PREDEL HG: Endogenous natriuretic and ouabain-likE factors. Their roles in body fluid volume and blood pressure regulation. J Hypertens 4:81-89, 1991
20. MASCHIO G: Erythropoietin and systemic hypertension. Nephrol Dial Transplant 10(Suppl 2):74-79, 1995
21. VAZIRI ND, ZHOU XJ, NAOVI F, SMITH J, OVEISI F, WANG ZQ, PURDY RE: Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am J Physiol (Encrinol Metab) 271:E113-E122, 1996
22. LUSCHER TF: Imbalance between endothelium-derived relaxing and contracting factors: A new concept in hypertension. Am J Hypertens 3.317-336, 1990
23. RUBANYI GM, VANHOUTTE PM: Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 250: H822-H827, 1986
24. GRYGLEWSKI RJ, PALMER RMJ, MONCADA S: Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 320:454-456, 1986
25. MCCALI TB, BOUGHTON-SMITH NK, PALMER RMJ: Synthesis of nitric oxide from L-arginine by neutrophils. Release and interaction with superoxide anion. Biochem J 261:293-296, 1992
26. 1) cell injury. Am J Physiol 268:F30-F38, 1995
27. SHERIDAN AM, FITZPATRICK S, WANG C, WHEELER DC, LIEBERTHAL W: Lipid peroxidation contributes to hydrogen peroxide induced cytotoxicity in renal epithelial cells. Kidney Int 49:88-93, 1996
28. 2-isoprostane production and cytolysis in renal tubular epithelial cells. J Am Soc Nephrol 6:1300-1303, 1995
29. 2 receptors. J Clin Invest 90:136-141, 1992
30. 2 and thromboxane induced vaso- and bronchoconstriction in rat perfused lung. J Appl Physiol 71:1309-1334, 1991
31. LIN PJ, PEARSON PJ, CARTIER R, SCHAFF HV: Superoxide anion mediates the endothelium-dependent contractions to serotonin by regenerated endothelium. Throrac Cardiovasc Surg 102:378-385, 1991
32. TESFAMARIAM B, COHEN RA: Role of superoxide anion and endothelium in vasoconstrictor action of prostaglandin endoperoxide. Am J Physiol 262:H1915-H1919, 1992
33. VAZIRI ND, DING Y, NI Z, GONICK HC: Altered nitric oxide metabolism and increased oxygen free radical activity in lead-induced hypertension: Effect of lazaroid therapy. Kidney Int 52:1042-1046, 1997
34. BRAMAN RS, HENDRIX SA: Nanogram nitrite and nitrate determination in environmental and biological materials by vanadium (III) reduction with chemiluminescence detection. Anal Chem 61:2715-2718, 1989
35. NI Z, MORCOS S, VAZIRI ND: Up-regulation of renal and vascular nitric oxide synthase in iron-deficiency anemia. Kidney Int 52:195-201, 1997
36. WONG SHY, KNIGHT JA, HOPFER SM, ZAHARIA O, LEACH CN, SUNDERMAN FW JR: Lipoperoxides in plasma as measured by liquid-chromatographic separation of malondialdehyde-thiobarbituric acid adduct. Clin Chem 33:214-220, 1987
37. VAZIRI ND, NI Z, WANG XQ, OVEISI F, ZHOU XJ: Down-regulation of nitric oxide synthase in chronic renal failure: Role of secondary hyperparathyroidism. Am J Physiol (Renal Physiol) (in press)
38. KAUPKE CJ, KIM S, VAZIRI ND: Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy. J Am Soc Nephrol 4:1874-1878, 1994